Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Pharmacovigilance and Drug Safety Software Market by Functionality (Adverse Event Reporting Software, Drug Safety Audits Software, Issue Tracking Software, Fully Integrated Software), by Deployment Mode (On Premise, Cloud) and by End User (Pharma and Biotech Companies, Contract Research Organizations, Business Process Outsourcing, Other): Global Opportunity Analysis and Industry Forecast, 2023-2032

A00775

Pages: NA

Charts: NA

Tables: NA

Drug safety management tool or software, that aids in reviewing, classifying, creating and other pharmacovigilance data is termed as PV software (or Pharmacovigilance software). The software also helps in the creation of adverse event reports. Furthermore, the PV software is majorly used by BPOs, contract research organizations (CROs ) and major pharmacovigilance solution providers.

There are several drivers, restraints and opportunities shaping the future of the market. Important factors including growing incidences of ADRs have played a major role in driving the pharmacovigilance and drug safety software market. Furthermore, rising adoption rate of such software by many outsourcing companies too have kept the future of the market bright. On the other hand, government entities including FDA, EMEA and others, has increased the pressure on the biotechnology and pharmaceutical brands to manufacture safe drugs. The aforesaid factor has also added to the increasing market share of the industry. However, lack of awareness about the benefits associated with the pharmacovigilance and drug safety software market has hampered its market growth. Regions such as Asia Pacific and Latin America are likely to create greater opportunities for the market.

The market is segmented based on functions, delivery model, end-customers and geography. Based on function the market segments discussed in the report consists of issue tracking solution, fully integrated solution, adverse event reporting solution etc. The mode of delivery assessed in the market research report includes on -demand and on premise delivery. The major end-customers examined during the study are pharma companies, CROs, BPOs and others. Geographies promising growth includes North America, Asia Pacific, Europe and LAMEA.

A closer look at the competitive landscape reveals that major IT brands are busy launching pharmacovigilance and drug safety software and generating clients in the same month itself. Prominent market players are also seen acquiring new companies or local market players to maintain their competitive edge. Other business strategies favored by the companies include constant upgradation, joint ventures and collaborations. Prominent market players discussed in the market research report are Oracle Corporation, Online Business Applications, Inc., Sparta Systems, Inc., United BioSource Corporation and others.

KEY BENEFITS FOR STAKEHOLDERS

  • The market research report provides an integrated information on the major drivers, restraints and opportunities influencing the industry growth during the forecast period.
  • The study further drills down to produce data volume by components, end customers and demography.
  • SWOT analysis of major brands, highlights weaknesses, strengths, opportunities and threats. The data proves effective for business owners planning on designing their marketing and branding strategies.
  • Region wise business performance discussed in the market research report would be valuable for enterprises planning to explore new areas.
  • The report not only examines the market dynamics but also takes a closer look at the growth rate and industrial chain structure.
  • Study further weigh up on the prominent market players and their business strategies to maintain their position.
  • Assessment of upstream and downstream market also forms an important part of the report.

 Key Market Segments

  • By Functionality
    • Adverse Event Reporting Software
    • Drug Safety Audits Software
    • Issue Tracking Software
    • Fully Integrated Software
  • By Deployment Mode
    • On Premise
    • Cloud
  • By End User
    • Pharma and Biotech Companies
    • Contract Research Organizations
    • Business Process Outsourcing
    • Other
  • By Region
    • North America
      • U.S.
      • Canada
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia

 
Key Market Players

  • Oracle Corporation.
  • United Biosource Corporation
  • Sarjen Systems Pvt. Ltd
  • Arisglobal
  • AB-Cube
  • Extedo GMBH.
  • Umbra Global
  • Ennov.
  • Sparta Systems, Inc
  • Online Business Applications, Inc

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY FUNCTIONALITY

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Functionality

    • 4.2. Adverse Event Reporting Software

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Drug Safety Audits Software

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Issue Tracking Software

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Fully Integrated Software

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY DEPLOYMENT MODE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Deployment Mode

    • 5.2. On Premise

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Cloud

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Pharma And Biotech Companies

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Contract Research Organizations

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Business Process Outsourcing

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Other

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Functionality

      • 7.2.3. Market Size and Forecast, By Deployment Mode

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Pharmacovigilance And Drug Safety Software Market

        • 7.2.6.1. Market Size and Forecast, By Functionality
        • 7.2.6.2. Market Size and Forecast, By Deployment Mode
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Pharmacovigilance And Drug Safety Software Market

        • 7.2.7.1. Market Size and Forecast, By Functionality
        • 7.2.7.2. Market Size and Forecast, By Deployment Mode
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Pharmacovigilance And Drug Safety Software Market

        • 7.2.8.1. Market Size and Forecast, By Functionality
        • 7.2.8.2. Market Size and Forecast, By Deployment Mode
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Functionality

      • 7.3.3. Market Size and Forecast, By Deployment Mode

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Pharmacovigilance And Drug Safety Software Market

        • 7.3.6.1. Market Size and Forecast, By Functionality
        • 7.3.6.2. Market Size and Forecast, By Deployment Mode
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Pharmacovigilance And Drug Safety Software Market

        • 7.3.7.1. Market Size and Forecast, By Functionality
        • 7.3.7.2. Market Size and Forecast, By Deployment Mode
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Pharmacovigilance And Drug Safety Software Market

        • 7.3.8.1. Market Size and Forecast, By Functionality
        • 7.3.8.2. Market Size and Forecast, By Deployment Mode
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Pharmacovigilance And Drug Safety Software Market

        • 7.3.9.1. Market Size and Forecast, By Functionality
        • 7.3.9.2. Market Size and Forecast, By Deployment Mode
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Pharmacovigilance And Drug Safety Software Market

        • 7.3.10.1. Market Size and Forecast, By Functionality
        • 7.3.10.2. Market Size and Forecast, By Deployment Mode
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Pharmacovigilance And Drug Safety Software Market

        • 7.3.11.1. Market Size and Forecast, By Functionality
        • 7.3.11.2. Market Size and Forecast, By Deployment Mode
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Pharmacovigilance And Drug Safety Software Market

        • 7.3.12.1. Market Size and Forecast, By Functionality
        • 7.3.12.2. Market Size and Forecast, By Deployment Mode
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Functionality

      • 7.4.3. Market Size and Forecast, By Deployment Mode

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Pharmacovigilance And Drug Safety Software Market

        • 7.4.6.1. Market Size and Forecast, By Functionality
        • 7.4.6.2. Market Size and Forecast, By Deployment Mode
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Pharmacovigilance And Drug Safety Software Market

        • 7.4.7.1. Market Size and Forecast, By Functionality
        • 7.4.7.2. Market Size and Forecast, By Deployment Mode
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Pharmacovigilance And Drug Safety Software Market

        • 7.4.8.1. Market Size and Forecast, By Functionality
        • 7.4.8.2. Market Size and Forecast, By Deployment Mode
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Pharmacovigilance And Drug Safety Software Market

        • 7.4.9.1. Market Size and Forecast, By Functionality
        • 7.4.9.2. Market Size and Forecast, By Deployment Mode
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Pharmacovigilance And Drug Safety Software Market

        • 7.4.10.1. Market Size and Forecast, By Functionality
        • 7.4.10.2. Market Size and Forecast, By Deployment Mode
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Pharmacovigilance And Drug Safety Software Market

        • 7.4.11.1. Market Size and Forecast, By Functionality
        • 7.4.11.2. Market Size and Forecast, By Deployment Mode
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Pharmacovigilance And Drug Safety Software Market

        • 7.4.12.1. Market Size and Forecast, By Functionality
        • 7.4.12.2. Market Size and Forecast, By Deployment Mode
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Pharmacovigilance And Drug Safety Software Market

        • 7.4.13.1. Market Size and Forecast, By Functionality
        • 7.4.13.2. Market Size and Forecast, By Deployment Mode
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Pharmacovigilance And Drug Safety Software Market

        • 7.4.14.1. Market Size and Forecast, By Functionality
        • 7.4.14.2. Market Size and Forecast, By Deployment Mode
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Functionality

      • 7.5.3. Market Size and Forecast, By Deployment Mode

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Pharmacovigilance And Drug Safety Software Market

        • 7.5.6.1. Market Size and Forecast, By Functionality
        • 7.5.6.2. Market Size and Forecast, By Deployment Mode
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Pharmacovigilance And Drug Safety Software Market

        • 7.5.7.1. Market Size and Forecast, By Functionality
        • 7.5.7.2. Market Size and Forecast, By Deployment Mode
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Pharmacovigilance And Drug Safety Software Market

        • 7.5.8.1. Market Size and Forecast, By Functionality
        • 7.5.8.2. Market Size and Forecast, By Deployment Mode
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Pharmacovigilance And Drug Safety Software Market

        • 7.5.9.1. Market Size and Forecast, By Functionality
        • 7.5.9.2. Market Size and Forecast, By Deployment Mode
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Pharmacovigilance And Drug Safety Software Market

        • 7.5.10.1. Market Size and Forecast, By Functionality
        • 7.5.10.2. Market Size and Forecast, By Deployment Mode
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Pharmacovigilance And Drug Safety Software Market

        • 7.5.11.1. Market Size and Forecast, By Functionality
        • 7.5.11.2. Market Size and Forecast, By Deployment Mode
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. AB-Cube

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Arisglobal

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Extedo GMBH.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Ennov.

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Online Business Applications, Inc

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Oracle Corporation.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Sarjen Systems Pvt. Ltd

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Sparta Systems, Inc

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. United Biosource Corporation

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Umbra Global

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET FOR ADVERSE EVENT REPORTING SOFTWARE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET FOR DRUG SAFETY AUDITS SOFTWARE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET FOR ISSUE TRACKING SOFTWARE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET FOR FULLY INTEGRATED SOFTWARE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET FOR ON PREMISE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET FOR CLOUD, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET FOR PHARMA AND BIOTECH COMPANIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET FOR BUSINESS PROCESS OUTSOURCING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET FOR OTHER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. NORTH AMERICA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 18. NORTH AMERICA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 19. U.S. PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 20. U.S. PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 21. U.S. PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 22. CANADA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 23. CANADA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 24. CANADA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 25. MEXICO PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 26. MEXICO PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 27. MEXICO PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 28. EUROPE PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 29. EUROPE PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 31. EUROPE PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 32. FRANCE PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 33. FRANCE PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 34. FRANCE PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 35. GERMANY PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 36. GERMANY PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 37. GERMANY PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 38. ITALY PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 39. ITALY PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 40. ITALY PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 41. SPAIN PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 42. SPAIN PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 43. SPAIN PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 44. UK PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 45. UK PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 46. UK PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 47. RUSSIA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 48. RUSSIA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 49. RUSSIA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 50. REST OF EUROPE PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 51. REST OF EUROPE PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 52. REST OF EUROPE PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 53. ASIA-PACIFIC PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 54. ASIA-PACIFIC PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 56. ASIA-PACIFIC PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 57. CHINA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 58. CHINA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 59. CHINA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 60. JAPAN PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 61. JAPAN PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 62. JAPAN PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 63. INDIA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 64. INDIA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 65. INDIA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 66. SOUTH KOREA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH KOREA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 68. SOUTH KOREA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 69. AUSTRALIA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 70. AUSTRALIA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 71. AUSTRALIA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 72. THAILAND PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 73. THAILAND PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 74. THAILAND PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 75. MALAYSIA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 76. MALAYSIA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 77. MALAYSIA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 78. INDONESIA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 79. INDONESIA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 80. INDONESIA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 81. REST OF ASIA PACIFIC PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 84. LAMEA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 85. LAMEA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 87. LAMEA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 88. BRAZIL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 89. BRAZIL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 90. BRAZIL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 91. SOUTH AFRICA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 92. SOUTH AFRICA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 93. SOUTH AFRICA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 94. SAUDI ARABIA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 95. SAUDI ARABIA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 96. SAUDI ARABIA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 97. UAE PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 98. UAE PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 99. UAE PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 100. ARGENTINA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 101. ARGENTINA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 102. ARGENTINA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 103. REST OF LAMEA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY FUNCTIONALITY, 2025-2033 ($MILLION)
  • TABLE 104. REST OF LAMEA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY DEPLOYMENT MODE, 2025-2033 ($MILLION)
  • TABLE 105. REST OF LAMEA PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 106. AB-CUBE: KEY EXECUTIVES
  • TABLE 107. AB-CUBE: COMPANY SNAPSHOT
  • TABLE 108. AB-CUBE: OPERATING SEGMENTS
  • TABLE 109. AB-CUBE: PRODUCT PORTFOLIO
  • TABLE 110. AB-CUBE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. ARISGLOBAL: KEY EXECUTIVES
  • TABLE 112. ARISGLOBAL: COMPANY SNAPSHOT
  • TABLE 113. ARISGLOBAL: OPERATING SEGMENTS
  • TABLE 114. ARISGLOBAL: PRODUCT PORTFOLIO
  • TABLE 115. ARISGLOBAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. EXTEDO GMBH.: KEY EXECUTIVES
  • TABLE 117. EXTEDO GMBH.: COMPANY SNAPSHOT
  • TABLE 118. EXTEDO GMBH.: OPERATING SEGMENTS
  • TABLE 119. EXTEDO GMBH.: PRODUCT PORTFOLIO
  • TABLE 120. EXTEDO GMBH.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 121. ENNOV.: KEY EXECUTIVES
  • TABLE 122. ENNOV.: COMPANY SNAPSHOT
  • TABLE 123. ENNOV.: OPERATING SEGMENTS
  • TABLE 124. ENNOV.: PRODUCT PORTFOLIO
  • TABLE 125. ENNOV.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 126. ONLINE BUSINESS APPLICATIONS, INC: KEY EXECUTIVES
  • TABLE 127. ONLINE BUSINESS APPLICATIONS, INC: COMPANY SNAPSHOT
  • TABLE 128. ONLINE BUSINESS APPLICATIONS, INC: OPERATING SEGMENTS
  • TABLE 129. ONLINE BUSINESS APPLICATIONS, INC: PRODUCT PORTFOLIO
  • TABLE 130. ONLINE BUSINESS APPLICATIONS, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 131. ORACLE CORPORATION.: KEY EXECUTIVES
  • TABLE 132. ORACLE CORPORATION.: COMPANY SNAPSHOT
  • TABLE 133. ORACLE CORPORATION.: OPERATING SEGMENTS
  • TABLE 134. ORACLE CORPORATION.: PRODUCT PORTFOLIO
  • TABLE 135. ORACLE CORPORATION.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 136. SARJEN SYSTEMS PVT. LTD: KEY EXECUTIVES
  • TABLE 137. SARJEN SYSTEMS PVT. LTD: COMPANY SNAPSHOT
  • TABLE 138. SARJEN SYSTEMS PVT. LTD: OPERATING SEGMENTS
  • TABLE 139. SARJEN SYSTEMS PVT. LTD: PRODUCT PORTFOLIO
  • TABLE 140. SARJEN SYSTEMS PVT. LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 141. SPARTA SYSTEMS, INC: KEY EXECUTIVES
  • TABLE 142. SPARTA SYSTEMS, INC: COMPANY SNAPSHOT
  • TABLE 143. SPARTA SYSTEMS, INC: OPERATING SEGMENTS
  • TABLE 144. SPARTA SYSTEMS, INC: PRODUCT PORTFOLIO
  • TABLE 145. SPARTA SYSTEMS, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 146. UNITED BIOSOURCE CORPORATION: KEY EXECUTIVES
  • TABLE 147. UNITED BIOSOURCE CORPORATION: COMPANY SNAPSHOT
  • TABLE 148. UNITED BIOSOURCE CORPORATION: OPERATING SEGMENTS
  • TABLE 149. UNITED BIOSOURCE CORPORATION: PRODUCT PORTFOLIO
  • TABLE 150. UNITED BIOSOURCE CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 151. UMBRA GLOBAL: KEY EXECUTIVES
  • TABLE 152. UMBRA GLOBAL: COMPANY SNAPSHOT
  • TABLE 153. UMBRA GLOBAL: OPERATING SEGMENTS
  • TABLE 154. UMBRA GLOBAL: PRODUCT PORTFOLIO
  • TABLE 155. UMBRA GLOBAL: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SEGMENTATION
  • FIGURE 2. GLOBAL PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET
  • FIGURE 3. SEGMENTATION PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALPHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET
  • FIGURE 11. PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SEGMENTATION, BY BY FUNCTIONALITY
  • FIGURE 12. PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET FOR ADVERSE EVENT REPORTING SOFTWARE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET FOR DRUG SAFETY AUDITS SOFTWARE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET FOR ISSUE TRACKING SOFTWARE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET FOR FULLY INTEGRATED SOFTWARE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SEGMENTATION, BY BY DEPLOYMENT MODE
  • FIGURE 17. PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET FOR ON PREMISE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET FOR CLOUD, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET SEGMENTATION, BY BY END USER
  • FIGURE 20. PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET FOR PHARMA AND BIOTECH COMPANIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET FOR BUSINESS PROCESS OUTSOURCING, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET FOR OTHER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 25. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 26. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 27. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 28. COMPETITIVE DASHBOARD
  • FIGURE 29. COMPETITIVE HEATMAP: PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET
  • FIGURE 30. TOP PLAYER POSITIONING, 2024
  • FIGURE 31. AB-CUBE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. AB-CUBE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. AB-CUBE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. ARISGLOBAL: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. ARISGLOBAL: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. ARISGLOBAL: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. EXTEDO GMBH.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. EXTEDO GMBH.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. EXTEDO GMBH.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. ENNOV.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. ENNOV.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. ENNOV.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. ONLINE BUSINESS APPLICATIONS, INC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. ONLINE BUSINESS APPLICATIONS, INC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. ONLINE BUSINESS APPLICATIONS, INC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. ORACLE CORPORATION.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. ORACLE CORPORATION.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. ORACLE CORPORATION.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. SARJEN SYSTEMS PVT. LTD: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. SARJEN SYSTEMS PVT. LTD: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. SARJEN SYSTEMS PVT. LTD: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. SPARTA SYSTEMS, INC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. SPARTA SYSTEMS, INC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. SPARTA SYSTEMS, INC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 55. UNITED BIOSOURCE CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 56. UNITED BIOSOURCE CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 57. UNITED BIOSOURCE CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 58. UMBRA GLOBAL: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 59. UMBRA GLOBAL: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 60. UMBRA GLOBAL: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Pharmacovigilance and Drug Safety Software Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved